GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » ROA %

MedTech Acquisition (MedTech Acquisition) ROA % : -24.30% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. MedTech Acquisition's annualized Net Income for the quarter that ended in Jun. 2023 was $-3.98 Mil. MedTech Acquisition's average Total Assets over the quarter that ended in Jun. 2023 was $16.38 Mil. Therefore, MedTech Acquisition's annualized ROA % for the quarter that ended in Jun. 2023 was -24.30%.

The historical rank and industry rank for MedTech Acquisition's ROA % or its related term are showing as below:

MTACU' s ROA % Range Over the Past 10 Years
Min: -1.02   Med: 3   Max: 4.09
Current: -1.02

During the past 3 years, MedTech Acquisition's highest ROA % was 4.09%. The lowest was -1.02%. And the median was 3.00%.

MTACU's ROA % is not ranked
in the Diversified Financial Services industry.
Industry Median: -0.845 vs MTACU: -1.02

MedTech Acquisition ROA % Historical Data

The historical data trend for MedTech Acquisition's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedTech Acquisition ROA % Chart

MedTech Acquisition Annual Data
Trend Dec20 Dec21 Dec22
ROA %
- 1.90 4.09

MedTech Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 1.05 -1.01 -8.80 -24.30

Competitive Comparison of MedTech Acquisition's ROA %

For the Shell Companies subindustry, MedTech Acquisition's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedTech Acquisition's ROA % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's ROA % distribution charts can be found below:

* The bar in red indicates where MedTech Acquisition's ROA % falls into.



MedTech Acquisition ROA % Calculation

MedTech Acquisition's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=5.539/( (250.533+20.188)/ 2 )
=5.539/135.3605
=4.09 %

MedTech Acquisition's annualized ROA % for the quarter that ended in Jun. 2023 is calculated as:

ROA %=Net Income (Q: Jun. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Jun. 2023 ))/ count )
=-3.98/( (20.52+12.238)/ 2 )
=-3.98/16.379
=-24.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2023) net income data. ROA % is displayed in the 30-year financial page.


MedTech Acquisition  (NAS:MTACU) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=-3.98/16.379
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.98 / 0)*(0 / 16.379)
=Net Margin %*Asset Turnover
=N/A %*0
=-24.30 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


MedTech Acquisition ROA % Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


MedTech Acquisition (MedTech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
48 Maple Avenue, Greenwich, CT, USA, 06830
Website
MedTech Acquisition Corp is a blank check company.
Executives
Magnetar Financial Llc 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc 10 percent owner 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman 10 percent owner C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell director 222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin director, 10 percent owner, officer: Chief Financial Officer
Karim Karti director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey director, 10 percent owner, officer: Chief Executive Officer 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss officer: Chief Admin Officer and Sec. 585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022

MedTech Acquisition (MedTech Acquisition) Headlines